Skip to main content

Advertisement

Table 2 Characteristics of healthy controls, hypertensive patients with and without hydrochlorothiazide treatment and patients with type 2 diabetes with and without SGLT2 inhibitor treatment

From: Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy

Variable Healthy Hypertensive with HCT Hypertensive without HCT Type 2 diabetes with SGLT2 inhibitor Type 2 diabetes without SGLT2 inhibitor ANOVA p
n 16 14 16 13 5 na
Age (years) 50 (35; 61) 56 (48; 63) 52 (43; 58) 64 (56; 71) 56 (54; 73) 0.0098
Sex (male) 4 (25%) 3 (21%) 5 (31%) 4 (31%) 5 (100%) 0.0472
BMI (kg/m2) 29.0 (24.8; 30.4) 30.1 (25.6; 33.4) 28.8 (25.0; 32.5) 32.7 (27.8; 37.6) 32.2 (30.5; 35.6) 0.1195
Body weight (kg) 74.9 (71.1; 84.5) 78.6 (71.0; 100.8) 83.2 (67.4; 95.4) 87.0 (72.6; 113.5) 89.7 (65.8; 98.9) 0.1409
Creatinine (mg/dL) 0.7 (0.6; 0.9) 0.8 (0.7; 0.8) 0.8 (0.6; 1.0) 0.7 (0.5; 0.9)a 0.6 (0.6;0.9) 0.5019
Proteinuria (mg/g creatinine) 12.6 (6.3; 16.2) 19.3 (13.5; 24.0) 11.4 (10.2; 18.3) 136 (69;197)a 137 (120; 619) < 0.0001
Renin (ng Ang L/mL/h) 1.3 (0.4; 3.1) 1.8 (0.3; 5.6) 2.8 (0.7; 6.7) 2.5 (0.9; 7.5) 4.5 (2.3; 21) 0.0986
Aldosterone (pg/mL) 161 (123; 194) 106 (75; 163) 102 (96; 146) 79 (64; 105) 112 (68; 147) 0.0254
Medication with RAAS inhibitor 0 11 (79%) 14 (88%) 12 (92%) 5 (100%) na
  1. Values reported are n (%) for categorical variables and median (interquartile range) for continuous variables. Values reported for patients with type 2 diabetes with SGLT2 inhibitor are values measured at the end of follow up period (day 180 of medication with SGLT2 inhibitor). Hypertensive patients with hydrochlorothiazide treatment included have taken hydrochlorothiazide for at least 6 months
  2. HCT hydrochlorothiazide, OH overhydration, ECW extracellular water, RAAS renin–angiotensin–aldosterone system, na not applicable
  3. aOnly baseline value available